GlaxoSmithKline Intellectual Property Development Limited
发明人:
Harling, John David,Tinworth, Christopher
申请号：
AU2017277596
公开号：
AU2017277596A1
申请日:
2017.06.08
申请国别(地区):
AU
年份:
2018
代理人:
摘要：
A method of treating disorders associated with aberrant kinase activity, wherein the kinase is. IRAK3, GAK, TEC, PTK2B(PYK2), AURKA, RPS6KAKRSK3), MAPK9(JNK2), BTK, PTK2 or AKT2., said method comprising degrading said kinase using compounds of Formula (I): Target Protein Binder - Linker - IAP binder (I)
